Clinical Trial Update: Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating bevacizumab, sorafenib tosylate, and temsirolimus in metastatic kidney cancer has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Cancer Ajcc V7
• Renal Cell Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Sorafenib tosylate (sorafenib tosylate)
• Temsirolimus (temsirolimus)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2015-05-05